

23. **(New)** The pharmaceutical composition according to claim 22, wherein said alcoholic extract comprises at least about 20-60% v/v of ethanol.
24. **(New)** The method according to claim 22, wherein said alcoholic extract comprises at least about 40-50% v/v of ethanol.
25. **(New)** The pharmaceutical composition according to claim 21, wherein said extract comprises St. John's wort extract.
26. **(New)** The pharmaceutical composition according to claim 25, wherein said St. John's wort extract is present in an amount of at least 5% by weight.
27. **(New)** The pharmaceutical composition according to claim 20, wherein the carrier comprises an ointment.
28. **(New)** The pharmaceutical composition according to claim 20, wherein the carrier comprises a cream.
29. **(New)** The pharmaceutical composition according to claim 20, wherein hyperforin is present in a concentration of at least about 15 µg per ml.
30. **(New)** The pharmaceutical composition according to claim 20, wherein hyperforin is present in a concentration of at least about 1-20 mg per ml.
31. **(New)** The pharmaceutical composition according to claim 20, wherein hyperforin is present in a concentration of at least about 0.02-20 mg per ml.
32. **(New)** The pharmaceutical composition according to claim 20, wherein said composition further comprises hypericins in a concentration of at least about 15 µg per ml.
33. **(New)** A method of preparing a pharmaceutical composition comprising the step of mixing:
- a) either i) an effective amount of hyperforin, or ii) an effective amount of hyperforin and hypericins; and
 - b) a carrier acceptable for topical administration.

34. **(New)** The method according to claim 33, wherein said effective amount of hyperforin and hypericins is in the form of an extract.

35. **(New)** The method according to claim 34, wherein said extract comprises St. John's wort extract.

36. **(New)** A method for treating a disease selected from the group consisting of: cancer; inflammatory skin diseases; precancerous conditions; geriatric skin; and microbial skin infections, comprising administering to a skin of a subject in need thereof an effective amount of a composition according to claim 20.

37. **(New)** The method according to claim 36, wherein the disease is eczema.

38. **(New)** The method according to claim 36, wherein said disease is selected from the group consisting of: exsiccation eczemas; hyperkeratotic hand and foot eczemas; contact eczemas; atopic dermatitis; neurodermatitis; lichen simplex; prurigo simplex; lymphomas; leukemia; melanoma; epithelial pre-cancerous conditions; tumor metastases; and epithelial tumor.

39. **(New)** The method according to claim 36, wherein said subject is a mammal.